Actively Recruiting
Study of AI Biomarkers to Guide Neoadjuvant Chemotherapy for Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma
Led by Roswell Park Cancer Institute · Updated on 2026-07-23
100
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are collecting samples and information from patients with pancreatic ductal adenocarcinoma PDAC who will receive standard neoadjuvant chemotherapy treatments, either FOLFIRINOX or Gemcitabine plus Nab-paclitaxel. The study aims to identify blood or tumor tissue biomarkers that might help predict how patients respond to these treatments. This could support selecting the most appropriate therapy for future patients with similar biomarkers. Participants will undergo standard neoadjuvant chemotherapy based on current care guidelines. Two groups are observed patients with borderline resectable PDAC and those with resectable PDAC, classified according to National Comprehensive Cancer Network criteria. Blood samples and archival tumor tissue will be collected to analyze potential biomarkers related to treatment response. During the study, participants pathological responses to treatment will be retrospectively assessed for up to two years. Additional outcomes include survival status and tumor response evaluation using RECIST 1.1 criteria. The study involves monitoring patients clinical data and collecting biological samples without altering their usual care, aiming to gather information that could guide future treatment decisions.
CONDITIONS
Brief Title
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Research Team
C
Christos Fountzilas, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
